These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 19255904)

  • 21. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
    Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
    Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The echinocandin B producer fungus Aspergillus nidulans var. roseus ATCC 58397 does not possess innate resistance against its lipopeptide antimycotic.
    Tóth V; Nagy CT; Pócsi I; Emri T
    Appl Microbiol Biotechnol; 2012 Jul; 95(1):113-22. PubMed ID: 22555909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic implications for use of antifungal agents.
    Lewis RE
    Curr Opin Pharmacol; 2007 Oct; 7(5):491-7. PubMed ID: 17616480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anidulafungin: a new echinocandin with a novel profile.
    Vazquez JA
    Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?
    Espinel-Ingroff A; Cantón E
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():3-9. PubMed ID: 21420570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of CLSI broth macrodilution and microdilution methods for echinocandin susceptibility testing of 5 Candida species.
    Bopp LH; Baltch AL; Ritz WJ; Smith RP
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):320-2. PubMed ID: 21937187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anidulafungin: when and how? The clinician's view.
    George J; Reboli AC
    Mycoses; 2012 Jan; 55(1):36-44. PubMed ID: 21668526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of disk diffusion method compared to broth microdilution for antifungal susceptibility testing of 3 echinocandins against Aspergillus spp.
    Martos AI; Martín-Mazuelos E; Romero A; Serrano C; González T; Almeida C; Puche B; Cantón E; Pemán J; Espinel-Ingroff A
    Diagn Microbiol Infect Dis; 2012 May; 73(1):53-6. PubMed ID: 22480568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions between naturally occurring antifungal agents.
    Tóth V; Szilágyi M; Anton F; Leiter E; Pócsi I; Emri T
    Acta Biol Hung; 2013 Dec; 64(4):510-2. PubMed ID: 24275596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a role for statins in fungal infections?
    Bergman PW; Björkhem-Bergman L
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1391-400. PubMed ID: 24215244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unnatural tetradeoxy echinocandins produced by gene cluster design and heterologous expression.
    Yu X; Jiang Q; Chen X; Shu H; Xu Y; Sheng H; Yu Y; Wang W; Keller NP; Xu J; Wang P
    Org Biomol Chem; 2023 May; 21(17):3552-3556. PubMed ID: 36807630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent Insights into the Paradoxical Effect of Echinocandins.
    Wagener J; Loiko V
    J Fungi (Basel); 2017 Dec; 4(1):. PubMed ID: 29371498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and characterization of a novel family of selective antifungal compounds (CANBEFs) that interfere with fungal protein synthesis.
    Mircus G; Albert N; Ben-Yaakov D; Chikvashvili D; Shadkchan Y; Kontoyiannis DP; Osherov N
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5631-40. PubMed ID: 26149982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical and genetic characterization of fungal proline hydroxylase in echinocandin biosynthesis.
    Zhang F; Liu H; Zhang T; Pijning T; Yu L; Zhang W; Liu W; Meng X
    Appl Microbiol Biotechnol; 2018 Sep; 102(18):7877-7890. PubMed ID: 29987385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data.
    Zhao Y; Perlin DS
    J Fungi (Basel); 2020 Sep; 6(4):. PubMed ID: 32998224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence of invasive infections with
    Molendijk EBD; van der Velden WJFM; Aarntzen EHJG; Coolen JPM; Blijlevens NMA; Buil JB
    Leuk Lymphoma; 2023 Jun; 64(6):1199-1203. PubMed ID: 37078583
    [No Abstract]   [Full Text] [Related]  

  • 38. An introduction to the future of echinocandin therapy.
    Bassetti M
    J Antimicrob Chemother; 2018 Jan; 73(suppl_1):i2-i3. PubMed ID: 29304206
    [No Abstract]   [Full Text] [Related]  

  • 39. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
    Kordalewska M; Lee A; Park S; Berrio I; Chowdhary A; Zhao Y; Perlin DS
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632013
    [No Abstract]   [Full Text] [Related]  

  • 40. In Vitro Human Liver Model for Toxicity Assessment with Clinical and Preclinical Instrumentation.
    Madorran E; Kocbek Šaherl L; Rakuša M; Munda M
    Pharmaceutics; 2024 Apr; 16(5):. PubMed ID: 38794269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.